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ABSTRACT
The human XPBC/ERCC-3 gene, which corrects the
excision-repair defect in xeroderma pigmentosum
group B cells and the UV-sensitive CHO mutant 27-1
cells, appears to be expressed constitutively in various
cell types and tissues. We have analysed the structure
and functionality of the XPBC/ERCC-3 promoter.
Transcription of the XPBC/ERCC-3 gene is initiated
from heterogeneous sites, with a major startpoint
mapped at position - 54 (relative to the translation start
codon ATG). The promoter region does not possess
classical TATA and CAAT elements, but it is GC-rich
and contains three putative Spl-binding sites. In
addition, there are two elements related to the cyclic
AMP (cAMP)-response element (CRE) and the 12-0-
tetradecanoyl phorbol-1 3-acetate-response element
(TRE) in the 5'-flanking region. Transient expression
analysis of XPBCIERCC-3 promoter-CAT chimeric
plasmids revealed that a 127-bp fragment, spanning
position -129 to -3, is minimally required for the
promoter activity. Transcription of the XPBC/ERCC-3
promoter depends on the integrity of a putative
Spl -binding site in close proximity to the major cap
site. Band shift assays showed that this putative
Spl -binding site can interact specifically with a nuclear
factor, most likely transcription factor Spl (or an
Spl-like factor) in vitro.
INTRODUCTION
The nucleotide-excision repair pathway is one of the major
components of DNA repair systems in prokaryotes and
eukaryotes. This pathway removes a wide range of lesions,
including UV-induced photo-products as well as bulky chemical
adducts (see ref. 1 for a general review on DNA repair). Defects
in the excision repair system may have serious consequences for
the organism, such as the human cancer-prone syndrome
EMBL accession no. Z1 1495
xeroderma pigmentosum (XP), an autosomal, recessive hereditary
disease in which most patients have a defect in the early steps
of the excision repair pathway (2). The molecular mechanism
and the regulation of the excision repair system have been
extensively studied in Escherichia coli and there is good evidence
that some of the excision-repair genes (uvrA, uvrB, and uvrD)
constitute part of the inducible SOS regulon that responds to DNA
damage (3). In the yeast Saccharomyces cerevisiae, expression
of the RAD2, RAD7, and RAD23 genes, which function in
excision repair, is DNA-damage-inducible (4-6), whereas
transcription of other excision-repair genes, the RADI, RAD3,
and RADI0 genes, is not substantially affected by DNA damage
(4). The mechanism as well as the regulation of mammalian
excision repair systems are poorly understood. Recently, genes
correcting the excision-repair defect in XP group A and B cells,
the XPAC gene (XP-A-correcting gene) (7) and the
XPBC/ERCC-3 gene (8, 9), respectively, have been cloned.
Several other human excision-repair genes, the ERCC (excision
repair cross-complementing rodent repair deficiency) genes,
including ERCC-J, ERCC-2, ERCC-5, and ERCC-6 were also
cloned (10-13).
The human XPBC/ERCC-3 gene encodes a putative DNA
helicase and was initially cloned on the basis of its ability to
correct the excision-repair defect in CHO mutant 27-1 cells (8).
Subsequently, it was discovered that it complemented the
excision-repair defect in XP-B cells. A C-A transversion in the
splice acceptor site of the last XPBC/ERCC-3 intron, causing a
4-bp insertion in the mRNA and an inactivating frameshift at the
protein level, was found to underlie the molecular defect in XP
group B cells (9). The genomic structure of the human
XPBC/ERCC-3 gene has been established in a great detail (14).
The gene has a length of approximately 45 kb and consists of
at least 14 exons (14). The XPBC/ERCC-3 gene appears to be
constitutively expressed in various cell types and tissues, similar
to another DNA-repair gene ERCC-J (14, 15). Initial sequence
comparison of the XPBC/ERCC-3 5'-flanking region with the
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ERCC-1 promoter revealed two regions of conservation, a
pyrimidine-rich stretch preceded by a 12-nucleotide motif (box
I) (14, 15).
We initially have identified a 376-bp genomic fragment
containing the promoter of the XPBC/ERCC-3 gene (14). Here
we report further studies regarding the XPBC/ERCC-3 promoter,
in which we define the major transcription initiation site of the
XPBC/ERCC-3 gene and identify a 127-bp sequence as the
functional promoter. Our results suggest that transcription activity
of the XPBC/ERCC-3 promoter depends on the integrity of an
Spl-binding site in close proximity to the major cap site.
MATERIALS AND METHODS
Cell culture, DNA transfection, and CAT assay
HeLa TK- cells were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 2% fetal calf serum and
8% newborn calf serum, 100 units/ml of penicillin, and 50 p.g/ml
of streptomycin. Primary human foreskin fibroblasts (VH10 cells)
and SV40-transformed VH1O cells were cultured in a 1: 1 mixture
of DMEM and Ham's FlO supplemented with 10% fetal calf
serum and antibiotics. For transfection, cells were seeded at a
density of 1 x 106 cells/10-cm dish 24 h before transfection. The
cells were transfected with 10 4tg of DNA from each promoter-
CAT construct, using the calcium-phosphate precipitation method
(16). Approximately 48 h after transfection, cells were harvested
and a protein extract was prepared by three repeated freeze-thaw
cycles of 5 min in dry ice, followed by 5 min at 37°C, in 100
dil of 250 mM Tris-Cl (pH 7.8). Samples normalized for protein
content (100 ,sg) were assayed for CAT activity by previously
described procedures (17). CAT activity was quantified by liquid
scintillation counting of excised sections of thin layer
chromatography plates and expressed as percent conversion of
[14C]chloramphenicol to its acetylated derivatives.
RNA isolation and in vitro transcription
Cytoplasmic RNA was isolated by the NP-40 method (18). In
vitro transcription was performed according to the manufacturer's
instruction (Promega). The template was plasmid pHEP-3
(Fig. IB) in which the XPBC/ERCC-3 5'-flanking sequence (from
-370 to -1) was fused to the XPBC/ERCC-3 cDNA (9). (For
convenience, we use a numbering system in which + 1 denotes
the A in the initiation codon ATG).
Primer extension and RNase protection
Primer extension was carried out according to the published
protocol (18). A 20-mer oligonucleotide 5'-dCCCATGGCAGC-
TACAGCAGC-3' extending from +5 to -15 was used as a
primer. RNase protection was performed as described previously
(19). For detection of the endogenous XPBC/ERCC-3 transcripts,
a plasmid designated pHEP-4 was made in which a 459-bp
fragment containing the 5' flanking region, exon 1, and a portion
of exon 2 of XPBC/ERCC-3 was cloned into the vector pEP30
(a T7 and SP6 promoter-containing plasmid provided by P.W.
Laird). Plasmid pHEP-4 was created by subcloning the SmaI
(+ 89)-EcoRI (in the polyliker region of the vector) fragment from
pHEP-3 into pEP30. A second construct, designated pEP-cat3,
was generated to analyse the XPBC/ERCC-3 promoter-CAT
RNA. Plasmid pEP-cat3 was made by inserting a 533-bp StuI
(-280)-EcoRI (in the CAT gene) fragment from
p- 370/ -3)CAT (the plasmid described below) into the pEP30.
Construction of promoter-CAT reporter plasmids
Plasmid pHEP (14) was used as a source of all subcloned genomic
fragments. Plasmid pHEP-5 was created by the subcloning into
pEP30 of a 1.2-kb SnaI (-809)-SmaI fragment derived from
pHEP, which contains the 5 '-flanking region, the first exon, the
first intron, and a portion of the second exon ofXPBC/ERCC-3.
Plasmid p(-370/-3)CAT was constructed by subcloning the
368-bp Mung-Bean-nuclease-treated NcoI-NcoI fragment
(position -370 to -3) into the pBA-CAT (20) at the HindIll
site (blunt-ended with the Klenow fragment of DNA polymerase
I). Plasmids p(-809/-3)CAT and p(-341/-3)CAT were
generated by excising the 319-bp SstII (-49)-XhoI (in the
polylinker region of the vector) fragment of p(-370/-3)CAT
and replacing it with a 759-bp SstII (-49)-Safl (at the polylinker
region of the vector) fragment from pHEP-5 and a 290-bp SstII-
XAoI fragment amplified by the polymerase chain reaction,
respectively. The 290-bp Sstll-XoI fragment was amplified with
an XPBC/ERCC-3-specific primer 5'-dGCTCGAGCTCACAC-
ACACAT-3' and a CAT-specific primer 5'-dTACGATGCCA-
TTGGG-3' and then digested with SstII and XhoI. Plasmids
p(-280/-3)CAT, p(-169/-3)CAT, p(-129/-3)CAT,
p(-1 19/-3)CAT, and p(-l10/-3)CAT were created by Bal3l
deletions. Such deletions were obtained from p( - 809/ - 3)CAT
by linearizing it at the Stul site (at -280) of the XPBC/ERCC-3
promoter sequence and digesting with Bal31 exonuclease (4
units/20-ig of DNA) for 0 to 2 min at 30°C. After digestion
with BamHI (in the polylinker region of the vector) which
removed the XPBC/ERCC-3 sequences upstream of -280, the
DNA fractions containing the deleted plasmids were purified by
electrophoresis through low-melting temperature agarose gels,
treated with the Klenow fragment to repair the ends, and
recircularized. All constructs were verified by DNA sequencing
analysis.
DNA sequencing and computer analyses
Nucleotide sequences were determined by the chain termination
method (21). Sequence data were analysed on a VAX computer
using the software computer package of the Genetics Computer
Group (University of Wisconsin, Madison, WI).
Band shift assay
Band shift experiments were performed as described previously
(22). Crude nuclear extracts from HeLa TK- cells were kindly
provided by H. van Dam, Leiden, and were prepared as described
(22). Seven ,tg of nuclear extract was incubated with 10 fmol
of labeled probe and 2 Ag of poly(dI-dC).poly(dI-dC) at room
temperature for 30 min. Samples were loaded onto 4% native
polyacrylamide gels prepared in 25 mM Tris, 1 mM EDTA, and
190 mM glycine. Electrophoresis was performed at room
temperature for 2 h at 15 mA.
Oligonucleotides used either as probes or as competitors in the
band shift assays were obtained by annealing of 5'-agctAGAG-
GCGGGACATCCT-3' and 5'-gatcAGGATGTCCCGCCTCT-3'
(erccSp 1), 5 '-agctCGGGGCGGGGCGGGGC-3' and 5 '-gatcG-
CCCCGCCCCGCCCCG-3' (consSp 1), and 5 '-agctCCCGTG-
ACGTCACCCG-3' and 5 '-gatcCGGGTGACGTCACGGG-3'
(fibCRE) (23). The probes were labeled with the Klenow
fragment of DNA polymerase I. The lower-case letters indicate
the nucleotides incorporated into the probes in the labeling
reaction.
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RESULTS
Mapping of the major transcription initiation site of the
XPBC/ERCC-3 gene
As a first step to delineate the location of cis-acting regulatory
elements, we determined the transcription initiation site of the
XPBC/ERCC-3 gene both by primer extension and by RNase
protection.
First, the 5' end of XPBC/ERCC-3 transcript was localized
by primer extension. A 5'-end-labeled 20-mer oligonucleotide
complementary to sequences spanning position +5 to -15 was
hybridized to cytoplasmic RNA isolated from HeLa cells and
extended using MoMuLV reverse transcriptase. (For simplicity,
we use a numbering system in which + 1 denotes the A in the
presumed translation initiation codon ATG). As can be seen in
Fig. IA, multiple initiation sites were found. The major primer-
extended product, surrounded by a cluster of minor primer
A
MGATC 1 2
- 403-nt
extension stops, has a length of 59 nt corresponding to position
-54 (lane 1). In addition, a series of minor stops was found
further upstream, one of these (120 nt, corresponding to position
-115) could represent the cap site of the published cDNA
sequence (9).
To rule out the possibility that the major observed stop in the
primer extension reaction had been caused by pausing or
premature termination of the reverse transcriptase reaction, we
employed a synthetic RNA molecule as template for the primer
extension analysis. This RNA molecule was transcribed from the
plasmid template pHEP-3, in which the 5'-flanking region of
XPBC/ERCC-3 was ligated to the XPBC/ERCC-3 cDNA
(Fig. 1B). The synthetic RNA was subjected to primer extension
with the 20-mer oligonucleotide as described above. As shown
in Fig. IA Oane 2), the most abundant extension product (403
nt, including 28 nt of the plasmid linker sequences) was precisely
the size expected for the RNA molecule generated. No strong
stops were observed surrounding the major cap site (position
-54). This analysis validates the efficiency of the reverse
transcription reaction and suggests that neither the high G+C
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Fig. 1. Primer extension analysis of the transcription initiation sites of the human
XPBC/ERCC-3 gene. A. A 20-mer 5'-end-labeled oligonucleotide extending from
+5 to -15 was annealed to 20 jsg of HeLa cell RNA (lane 1) and extended
upstream with Murine Leukaemia Virus reverse transcriptase. An RNA molecule
generated by in vitro transcription from the plasmid template, pHEP-3, was
included in the same reaction in order to verify the efficiency of the reverse
transcription reaction (lane 2). B. Diagram of the plasmid template pHEP-3, the
RNA generated, and the expected extension product (403 nt). The resulting
products were analysed on a 6% polyacrylamide/8 M urea gel next to a sequencing
ladder (lanes G, A, T, and C). Numbers alongside the gel indicate the sizes of
labeled marker fragments (pBR322, digested with HpalI) (lane M). The major
extended product obtained with HeLa cell RNA has a length of 59 nt and is
indicated by a large arrow. A minor one with a length of 120 nt is indicated
by a small arrow. Additional minor products with size greater than 120 nt are
also observed.
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Fig. 2. RNase protection mapping of XPBC/ERCC-3 transcripts in HeLa cells.
A. Schematic representation of the plasmid template, the 32P-labeled RNA probe
derived from the template, and the expected protected RNA fragment for HeLa
cell transcripts. The uniformly labeled antisense RNA probe was transcribed from
the chimeric plasmid pHEP-4, in which the XPBC/ERCC-3 5'-flanking sequences
(from -370) were fused to the cDNA sequences extending to +89 inside exon
2. B. Electrophoretic analysis of protected fragments obtained by the use of 20
ug (lane 2) and 40 Ag (lane 3) HeLa cell RNA, or 20 Mg tRNA (lane 1) for RNase
protection. The two most abundant RNase-resistant bands (with lengths of 143
nt and 138 nt) are indicated by the large arrows. The two minor bands are indicated
by the small arrows. Lane M contains the molecular size markers (see Fig. IA).
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content nor a possible secondary structure of the mRNA can
account for the major stop observed in our primer extension
analysis.
The major cap site as determined by primer extension was
confirmed by RNase protection experiment. The results of this
analysis are shown in Fig. 2. Fig. 2A is a diagrammatic
representation of the plasmid template, the anti-sense RNA probe,
and the band expected to be protected. The probe was hybridized
with various amounts of HeLa cell RNA and digested with a
combination of RNases A and Ti. Two major RNase-resistant
bands, with lengths of 138 and 143 nucleotides, were detected
(Fig. 2B, lanes 2 and 3). Calculated from the position of initiator
codon ATG, they localize the 5' ends of the XPBC/ERCC-3
transcripts to positions -49 and -54, respectively. In addition,
two minor protected bands (158 nt and 174 nt) were observed
when the amount of RNA was raised to 50 itg (Fig. 2B, lane
3); the significance of these bands is not clear.
Cytoplasmic RNAs from primary VH1O fibroblasts, VH1O
cells (24 h) after UV-irradiation (16 J/m2), and SV40-trans-
formed VHIO cells were also examined by primer extension
analysis. The lengths and distribution pattern of the extension
products in all RNAs differed little from those observed for HeLa
cell RNA (data not shown), which indicated that the choice of
the major transcription initiation site does not seem to vary in
a cell-type-specific or a DNA-damage-dependent manner.
Considering all data, we conclude that transcription of the
XPBC/ERCC-3 gene is initiated from heterogeneous sites with
the major startpoint being located at position -54.
Structural analysis of the 5'-flanking region discerns putative
promoter elements
The nucleotide sequence of the XPBC/ERCC-3 5'-flanking region
is presented in Fig. 3. Comparison of the sequence with those
in the DNA data banks (EMBL, GCG version 6.0) revealed a
5' -CTTAAGGCCT TCAACTGATT
-880 TGGATGAGGC CCACCCGCAT TATTGACGGT AATCTGCTTT ATTTAGGCTG AGACATGAGA
-820 ATGGCATGAA CC,CGQT TTGCA GTGAGCTGAA ATCGCGCCAC TGCATTCCAG
-760 CCTGGGCGAC AGGGCGAGAC TCCGTCTCAA AAAAAAAAAA AAAAAAAGAA AAAAATTTTT
-700 TTTGAGACGA ACTCTCGGCC TCTCGCCWC _QTGTAGTGC AGTGGTGCAA TCTCAGCTCA
-640 GTGCAGCCTT TACCTTCTGG GTTCAAGAGA TTCTCCCATC TCAGCCTCCC AAGTAGCTTA
-580 GACTACAGGC GTGTGCCACC ATGCCTGGCT ACKTmTTTTT GTATTTTTCG CAGAGATGGG
-520 GTTTCACCAT GTTGGCCAGG CTGGCCTCGA ACTCCTGAC TCAAGTGATC CACCCACCTC
-460 AGCCTCCCAA AGTGCTGGAA TTACAGGCCGT GAGCCACCGT GCTCAGCCAA ATTTTTTTTA
-400 ATTAAAAAAA AGAATTCTTC CTTACCCATG GACTA cCATTCTCTC TCTCTCTCTC
-340 TCACACACAC ATTTATTGCC CACATGGCTT CATTAAAATT TAAGTTCCAG AAGGATGAGG
-280 CCTTTAATTC CCGCACTACA CAGGTGCTCA ACACACAGTA TTTTCCTTCA GTTGTAGAGA
-220 AATGAACAGT CGAGGACCSPgTogr TCGCACGAGC TAACAGATOG GCGGTCGCTG
-160 GCTCTCCGCT CTTCCAGCCA CCCACATCAC GGCGCCCTAGACCCGACT CCTGTGTGGA
-100 CAACAGGGAG CTTCCGGATT GAGCCGGAAG TCCCCCCAGA GCGGATG5CCG CGGCGGGCCT
- 40 GTGGGAGCGG GGTCATCTTC TCTCTOCTGC TTAOCTG=C ATGGOCAAAA-3'
-l +1
Fig. 3. Sequence of the XPBC/ERCC-3 S-flanking region. Bases are numbered
with respect to the initiation codon ATG (the A is + 1). Part of this sequence,
from -375 to + 10, has been previously reported (14) under accession number
M31899 with a different numbering system: nt -114 in the present system
corresponds to nt +1 in ref. 14. The location of the 20-mer oligonucleotide used
for the primer extension is in boldface. The major transcription startpoint (-54)
is indicated by an asterisk. Putative regulatory elements are underlined and
appropriately labeled.
290-bp Alu repeat sequence from -702 to -413 showing
approximately 84% similarity to a consensus Alu repeat (24).
A short segment of Alu-like sequence was found from - 836 to
-717. The element between -836 to -594 has the potential
to form a DNA cruciform, as predicted by computer analysis
(data not shown).
The XPBC/ERCC-3 promoter does not contain a canonical
TATA nor a CAAT box at their characteristic positions relative
to the transcription initiation site (25). The XPBC/ERCC-3
promoter region also lacks any identifiable housekeeping initiator
protein (HIP1)-binding sequences (26). The sequences
immediately surrounding the major cap site show some
resemblance to the 'initiator' element (27). Like many other genes
in which transcription is initiated from heterogeneous sites, the
XPBC/ERCC-3 promoter region (between -200 to -1) is GC-
rich (67 %) and comprises a total of 18 CpG dinucleotides. There
are several C/G clusters which might interact with transcription
factor ETF, a recently described nuclear factor that binds to
promoters without a TATA box (28). Furthermore, there are two
elements (position -805 to -796, GAGGCGGACG; and
position -122 to -113, GAGGCGGGAC) similar to the
recognition and binding site of transcription factor Spl (29, 30).
According to the numbering used in this study, the previously
described putative SpI -binding site (CCCCCGCCGC; 14) is at
position -204 to - 195. The pyrimidine-rich stretch and the
conserved motif (box I) which have been found in the promoters
of XPBC/ERCC-3 and ERCC-J, another human DNA excision-
repair gene (14, 15), are at position -357 to -339 and -369
to
-358, respectively.
Several ATTA boxes, which have been implicated in the
binding of homeobox proteins in vertebrates and in Drosophila
melanogaster (31), are present between position -442 to -272.
We also noticed the existence of a sequence motif (TCGCCC-
AGGC) resembling the consensus AP-2 site (32) at position -678
to -669. The sequence from -484 to -478 (TGACCTCA)
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Fig. 4. Transient-expression analysis of the 5' deletion mutants of XPBC/ERCC-3
promoter-CAT plasmids in HeLa TK- cells. A. Diagrammatic representation
of XPBC/ERCC-3 promoter-CAT chimeric constructs. The major transcription
initiation site determined in this study is indicated by an arrow. Numbers correspond
to the endpoints of the deletion mutants. B. Result of a representative CAT assay,
showing the relative activity of various 5' promoter deletions in HeLa TK- cells.
Cells were transiently transfected with 10 jg of each XPBC/ERCC-3 promoter-
CAT plasmid. After 48 h, cells were harvested and total cell extracts were
prepared. CAT activity was measured, quantified and expressed as the percentage
of conversion of chloramphenicol to its acetylated derivatives. The results of three
independent experiments were averaged to give the reported values of CAT activity
for each CAT-construct tested. One hundred yg of protein was used to assay
CAT activity. For pRSV-CAT, 2 yig of plasmid was used for transfection and
20 jg of protein for CAT assay.
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shows a high degree of similarity to the consensus cyclic AMP
(cAMP)-responsive element (CRE; TGACGTCA) and the 12-0-
tetradecanoyl phorbol-13-acetate-responsive element (TRE; TG-
A[C/G]TCA) (33 -35). For convenience, we will refer to this
motif as a CRE/TRE-related element. Interestingly, the sequence
from -367 to -360 in box I (TCAGGTCA) forms an almost
perfect inverted repeat with the CRE/TRE-related element. For
this reason we will refer to this sequence as an inverted
CRE/TRE-related element.
The pertinence of these putative elements for transcription
regulation can be confirmed only by functional mapping of the
promoter region.
Functional analysis defines the regulatory regions in the
XPBC/ERCC-3 promoter
To delineate the sequence elements required for XPBC/ERCC-3
gene transcription, we constructed a series of chimeric plasmids
containing various 5'-progressive deletion fragments fused
upstream to the bacterial CAT gene (Fig. 4A). The 5' deletion
mutants were created either by deleting restriction fragments or
by Bal3 1 exonuclease digestion. All of the 5' deletion fragments
had the same 3' endpoint at position -3 and were cloned into
the promoter-less pBA-CAT plasmid (20). These constructs were
transiently transfected into HeLa TK- cells and assayed for
CAT enzyme activity. In addition, pRSV-CAT containing the
Rous sarcoma virus (RSV) long terminal repeat (LTR) and pBA-
CAT, the parent plasmid, were included as constitutive positive
and negative controls, respectively. Fig. 4B shows the 5' deletion
analysis through the XPBC/ERCC-3 promoter.
Construct p(- 809/- 3)CAT, containing 807 bp of the
XPBC/ERCC-3 sequence, exhibited a promoter activity
comparable to that of the p(-370/-3)CAT (data not shown),
revealing that the putative AP-2 element and the CRE/TRE-
related element are not directly involved in the basal promoter
activity. Further deletion of the inverted CRE/TRE-related
element and the pyrimidine-rich stretch (construct
p(-341/-3)CAT) had, unexpectedly, no significant influence
on the basal promoter activity. Analysis of constructs
p(-280/ -3)CAT, p(-169/ -3)CAT, and p(-129/ -3)CAT
made clear that sequences up to -129 are dispensable for the
basal promoter activity. In marked contrast, deletion of only 10
bp between -129 and -119 (construct p(-119/-3)CAT),
which overlaps with the putative SpI-binding element in close
proximity to the major cap site, drastically reduced the expression
level (> 6-fold), suggesting that this region is absolutely required
for full promoter function. Although further deletion between
-119 to -110 (construct p(- 10/-3)CAT), reduced the CAT
activity to one-fifteenth of that mediated by p(- 129/ -3)CAT,
there still was some CAT activity to be detected, indicating that
the remaining region, too, might contain some weak promoter
activity.
Comparison of the levels of CAT enzyme activity (over a
concentration range of both plasmid and cellular-extract protein)
mediated by p(- 370/ -3)CAT and by pRSV-CAT in transient
assays in HeLa TK- cells, showed that in HeLa cells the
XPBC/ERCC-3 promoter has approximately 1% of the strength
of the RSV-LTR (data not shown).
Plasmids p(- 370/ -3)CAT and p(- 129/ -3)CAT were also
transfected into primary VH1O and SV40-transformed VH1O
fibroblasts. In spite of the low transfection efficiency, both
constructs were equally active in human fibroblasts (data not
shown).
Taken together, these results demonstrated that a 127-bp
fragment, from -129 to -3, is minimally required for basal
promoter activity of the XPBC/ERCC-3 gene. Furthermore,
transcription activity of the XPBC/ERCC-3 promoter is very
much dependent on the integrity of the putative SpI-binding site
in close proximity to the major cap site.
To verify that in transient assays the major cap site is properly
used, RNase protection was performed with cytoplasmic RNA
isolated from transiently transfected HeLa cells. Fig. 5A presents
a schematic diagram of the plasmid template, the RNA probe,
and the products expected to resist RNase digestion. The results
of RNase protection are shown in Fig. SB. The pRSV-CAT
transcript (lane 4) protected a fragment of 254 nt, precisely the
size expected for the 5' terminus of the CAT gene. Transcripts
from p(-370/-3)CAT (lane 5) and p(- 129/-3)CAT (lanes 6)
protected fragments with the same length of 308 nt. This fragment
B
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Fig. 5. RNase protection analysis of transiently transfected promoter-CAT
constructs. A. Structure of the antisense RNA probe used in RNase protection.
A 533-nt StuI-EcoRI fragment, which contains the XPBC/ERCC-3 promoter-CAT
sequence from position -280 (to -3) of the XPBC/ERCC-3 promoter sequence
to the EcoRI site in the CAT gene, was cloned into pEP30 and a uniformly labeled
antisense RNA probe was generated by T7 polymerase transcription. The expected
protected fragments for XPBC/ERCC-3 promoter-CAT transcripts (308-nt) and
for the pRSV-CAT transcript (254-nt) are indicated. B. Cytoplasmic RNA was
prepared from HeLa TK- cells 48 h after transfection with constructs
p(-370/-3)CAT, p(- 129/-3)CAT, and the control pRSV-CAT, respectively.
Twenty 1og of cytoplasmic RNA was hybridized with the uniformly labeled RNA
probe, as shown in (A), and digested with RNases A and TI. Lanes: 1, input
probe; 2, tRNA control; 3, RNA isolated from nontransfected HeLa cells as a
negative control; 4, 5, and 6, RNA isolated from pRSV-CAT, p(-370/-3)CAT,
and p(- 129/-3)CAT transfected HeLa cells, respectively.
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defines a transcription initiation site which is in complete
agreement with the major transcription startpoint of the
endogenous XPBC/ERCC-3 gene as described above.
The putative Spl-binding element interacts specifically with
a nuclear factor in vitro
Our transient transfection assays established that the putative
Spl-binding site in close proximity to the major cap site is
essential for the basal XPBC/ERCC-3 promoter activity. SpI was
one of the first mammalian transcriptional activators to be
described, and it binds specifically to a GC-box found in many
viral and cellular promoters (29, 30). To determine whether the
putative SpI-binding site in close proximity to the major cap site
ofXPBC/ERCC-3 is able to interact with transcription factor(s),
we conducted a gel-mobility-shift assay. A 32P-labeled double-
stranded oligonucleotide, erccSpl, covering the DNA region from
- 123 to -108 in the XPBC/ERCC-3 promoter (Fig. 6A) was
incubated with a crude nuclear extract from HeLa TK- cells
and then analysed by gel electrophoresis. As shown in Fig. 6B
(lane 1), it formed two complexes in the presence of the
nonspecific competitor poly(dI-dC)-poly(dI-dC). Both complexes
were also detected with the oligonucleotide consSpl (Fig. 6B,
Fig. 6. Band shift assays of the XPBC/ERCC-3 SpI element. A. The
oligonucleotide probe, erccSpl, used for band shift assay is aligned below the
segment of the XPBC/ERCC-3 promoter from - 132 to - 103. The 5' endpoints
of three deletions within this region (-129, -119, and -110) are also indicated.
An oligonucleotide, consSpl, containing a consensus Sp 1-binding site was used
as the sequence-specific competitor. The lower-case letters indicate the nt
incorporated into the probes in the labeling reaction. B. Oligonucleotide probes
erccSpl (lanes 1 to 6) and consSpl (lanes 7 to 12) were incubated with 7 jUg
crude nuclear extracts from HeLa TK- cells in the absence or presence (either
10- or 100-fold molar excess) of unlabeled oligonucleotide competitors as indicated
above the lanes. The protein-DNA complexes formed with erccSpl and consSpl
are indicated.
lane 7) which contains a high-affinity binding consensus of
nuclear factor Spl (Fig. 6A) (30). The upper complex resolves
into two distinct bands on lower exposures (data not shown) which
are consistent with the existence of two forms of Spl (105 and
95 kDa) (29, 36). The lower complex, which showed binding
affinity and a competition pattern identical to that of Spl, might
represent a degradation or posttranslational product of Spl (37,
38) or a factor distinct from Spl as suggested by Refs. (39, 40).
To determine the specificity and affinity of the binding, we
carried out a series of competition experiments. An unrelated
oligonucleotide, fibCRE (see Materials and Methods), which
contains the CRE sequence of the fibronectin promoter (23), was
included as a negative control. The complex formed with labeled
fibCRE was almost completely disrupted by a 10-fold molar
excess of unlabeled fibCRE, whereas a 100-fold excess of either
unlabeled erccSpl or unlabeled consSpl was unable to do so (data
not shown). The DNA-protein complex formed with the
XPBC/ERCC-3 Spl element (lane 1) could be disrupted either
by an excess of unlabeled erccSpl oligonucleotide (lanes 2 and
3) or by an excess of consSpl oligonucleotide (lanes 4 and 5)
and vice versa (lanes 7 to 11), whereas fibCRE oligonucleotide
could compete for none of the complexes (lanes 6 and 12); this
established a relatedness in the binding specificity between the
XPBC/ERCC-3 Spl element and the consensus SpI element. It
seems that the XPBC/ERCC-3 SpI element has a slightly lower
affinity in protein binding than the consensus Spl element, since
a 100-fold excess of the consSpl oligonucleotide could abolish
the complexes formed with the XPBC/ERCC-3 Spl element
almost completely (lane 5), whereas a 100-fold excess of the
erccSpl oligonucleotide had only a slight effect on the retardation
complexes formed with the consensus Sp 1 element (lane 9).
DISCUSSION
The human XPBC/ERCC-3 gene, encoding a putative DNA
helicase, is involved in an early step of nucleotide-excision repair
and turned out to be the XP-B-correcting gene. Here we present
a structural and functional analysis of the XPBC/ERCC-3
promoter, the first mammalian DNA-repair gene promoter to be
examined. The major transcription initiation site of the
XPBC/ERCC-3 gene has been determined by a combination of
primer extension and RNase protection. Deletion analysis of the
promoter-CAT reporter genes localizes the functional promoter
region and reveals that transcription activity of the XPBC/ERCC-3
promoter depends on the integrity of a putative Spi-binding site.
This putative SpI-binding site can interact specifically with a
nuclear factor, most likely transcription factor SpI or an Spl-like
factor, in vitro.
The XPBC/ERCC-3 upstream region resembles the promoter
sequences of some so-called 'housekeeping' genes (41), such as
those encoding adenosine deaminase (42), hypoxanthine phos-
phoribosyl transferase (HPRT) (43), and 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG CoA) reductase (44), as well as the
5'-regions of some growth-related genes, such as those encoding
the rat transforming growth factor (45), the epidermal-growth-
factor receptor (46), and c-Harvey ras (47). Lack of typical
TATA and CAAT boxes, but a high G+C content, multiple GC-
boxes, and a heterogeneity of transcription initiation sites appear
to be the characteristic features of the promoter regions of such
genes (41). The XPBC/ERCC-3 promoter also lacks canonical
TATA and CAAT boxes, is GC-rich (from -200 to -1, 67 %
G + C), and contains three putative Spl -binding sites. XPBC/
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ERCC-3 mRNA initiates from multiple sites; the major tran-
scription startpoint is located at 54 nt upstream of the presumed
initiator codon ATG. Additional minor initiation sites extending
beyond this region are also observed, and one of these (at -115)
could be consistent with the cap site previously presumed by us
(14) and account for the 5' end of the published XPBC/ERCC-3
cDNA clones (9). The choice of the major cap site does not seem
to vary in a cell-type-specific or DNA-damage-dependent manner.
In transient assays with XPBC/ERCC-3 promoter-CAT
constructs, we observed only one single initiation site,
corresponding to the major startpoint of the endogenous gene.
We assume that other distal cis-acting elements are required for
the heterogeneity of transcription initiation which are absent in
our promoter-CAT constructs.
Using a series of 5'3' deletion mutants, we have shown that
the promoter element required for the full level of expression
in transient assays resides within a stretch of XPBC/ERCC-3
sequence extending from -129 to - 3 (construct
p(- 129/-3)CAT). Further deletion studies indicated that the
integrity of a putative Spl-binding site in close proximity to the
major cap site is a prerequisite for active transcription of the
XPBC/ERCC-3 promoter. Furthermore, this SpI element is well
conserved between mouse and human XPBC/ERCC-3 promoters
(48), supporting our conclusion that transcription factor Spl is
important for regulation of the XPBC/ERCC-3 gene.
Band shift assays demonstrated that the putative Spl-binding
site in close proximity to the major cap site of XPBC/ERCC-3
can interact specifically with a nuclear factor in vitro. An
oligonucleotide containing a consensus Spl-binding site
specifically competed with the putative XPBC/ERCC-3 Spl
element in forming DNA-protein complexes and vice versa.
Therefore, it is most likely that the protein which complexes to
the XPBCIERCC-3 Spl element represents transcription factor
Spl. The competition studies indicated that the XPBC/ERCC-3
Spl element might have a lower affinity for Spl binding than
the consensus Spl-binding site. However, binding affinity is not
the only determinant for Spl activation. Earlier work has
established that in promoters containing multiple Spl-binding
elements the most important one is usually the one closest to the
gene, approximately 40-70 nucleotides upstream of the
transcription initiation site (30). Even weak Spl-binding sites,
such as GC-box I in the herpes simplex virus I (HSV) thymidine
kinase (TK) promoter (49) and that in the SV40 early promoter
(50), might well be very important for transcriptional activation.
Recently, transcription factors other than the Spl factor which
also interact with the GC-box have been identified (40, 51). We
presently have no evidence for or against the possible involvement
of other transcription factors than Spl itself interacting with the
XPBC/ERCC-3 Spl element.
Polypurine-polypyrimidine sequences have recently attracted
much attention since they can form an unusual hairpin triplex
structure (52). The function of the polypyrimidine motif is
unknown at present. The pyrimidine-rich stretch in the ERCC-2
promoter has been suggested to play a role in stable ERCC-2
expression, since a cosmid lacking this sequence can only confer
transient UV-resistance to UV5 cells (11). It has been suggested
that the pyrimidine-rich stretch conserved between the promoters
ofXPBC/ERCC-3 and ERCC-1 may also play a role in regulation
of the expression of XPBC/ERCC-3 as well as ERCC-J (14).
Deletion of the pyrimidine-rich stretch, however, does not affect
the XPBC/ERCC-3 promoter activity in transient assays. We do
not know whether this element has any other direct effect on the
local chromatin structure at the XPBC/ERCC-3 locus, for
example, in the regulation of the XPBC/ERCC-3 gene expression.
Finally, the existence of CRE/TRE-related elements and a
putative AP-2 element in the XPBC/ERCC-3 promoter makes
it interesting to investigate whether cAMP/TPA and/or UV-light
is able to induce the expression of the XPBC/ERCC-3 gene. In
mammalian cells, DNA damage leads to activation of the UV
response with a putative role to protect cells against the effects
of DNA damage. Interestingly, several mam an phorbol
esters-inducible genes are also induced by DNA damage (53).
The UV- and phorbol-ester-response element of the collagenase
promoter coincides with the AP-1 (c-Fos/c-Jun) binding site (22,
33). Recent studies with the c-jun gene identified AP-1 binding
elements as likely regulators of gene activation during the
mammalian UV response; however, the data suggested that DNA
damage activates AP-1 by a mechanism that differs from that
by TPA (54). Our preliminary data have demonstrated the
CRE/TRE-related element as well as the inverted one in the
XPBC/ERCC-3 promoter can interact with nuclear factors in vitro
(data not shown). Since the XPBC/ERCC-3 gene is one of the
few mammalian DNA excision repair genes that have been
characterized so far, investigation of the possible induction by
UV as well as by TPA and/or cAMP might shed some light on
the question whether the mammalian DNA excision repair
pathway is a component of the mammalian UV response.
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